MANILA—A Chinese biotech firm is planning to conduct a clinical trial in the Philippines for its experimental prostate cancer drug as treatment against COVID-19 infection, the Department of Health disclosed Friday.
The drug called proxalutamide, which is developed by Kintor Pharmaceuticals, is a nonsteroidal antiandrogen originally conceived for the treatment of prostate and breast cancer, Health Undersecretary Maria Rosario Vergeire said. "Meron na pong nakasalang na magiging trial dito sa atin sa Pilipinas and they have identified the Lung Center of the Philippines for this. They are currently processing the contract," she said in a press briefing.Kintor previously touted a Brazilian study of proxalutamide, which claimed a high effectiveness rate.
The Brazil study said proxalutamide showed a 92 perent reduction in mortality risk among hospitalized COVID-19 patients.The Brazil study of the drug has not been peer-reviewed or published, but the authors released a short presentation of its results during a March news conference. One of the study's authors, Brown University dermatology professor Carlos Wambier, called its results "very encouraging."
Patay Tayo Dyan’ Ginawang Guinea Pig ang Pinoy
Start with Duterte, para deads agad...
Philippines Latest News, Philippines Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: inquirerdotnet - 🏆 3. / 86 Read more »
Source: manilabulletin - 🏆 25. / 51 Read more »
Source: ANCALERTS - 🏆 26. / 50 Read more »
Source: ABSCBNNews - 🏆 5. / 83 Read more »
Source: inquirerdotnet - 🏆 3. / 86 Read more »
Source: manilabulletin - 🏆 25. / 51 Read more »